SG10201405069QA - Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) - Google Patents

Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Info

Publication number
SG10201405069QA
SG10201405069QA SG10201405069QA SG10201405069QA SG10201405069QA SG 10201405069Q A SG10201405069Q A SG 10201405069QA SG 10201405069Q A SG10201405069Q A SG 10201405069QA SG 10201405069Q A SG10201405069Q A SG 10201405069QA SG 10201405069Q A SG10201405069Q A SG 10201405069QA
Authority
SG
Singapore
Prior art keywords
coenzyme
sarcoma
treatment
methods
epimetabolic shifter
Prior art date
Application number
SG10201405069QA
Inventor
Rangaprasad Sarangarajan
Niven Rajin Narain
John Patrick Mccook
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG10201405069QA publication Critical patent/SG10201405069QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG10201405069QA 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) SG10201405069QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25

Publications (1)

Publication Number Publication Date
SG10201405069QA true SG10201405069QA (en) 2014-10-30

Family

ID=43730801

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012012704A SG178547A1 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
SG10201405069QA SG10201405069QA (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012012704A SG178547A1 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Country Status (15)

Country Link
US (2) US20110064747A1 (en)
EP (1) EP2470169A4 (en)
JP (2) JP6159085B2 (en)
KR (1) KR101572463B1 (en)
CN (2) CN102548549A (en)
AU (2) AU2010292532A1 (en)
BR (1) BR112012004237A8 (en)
CA (1) CA2772068C (en)
CR (1) CR20120120A (en)
EA (1) EA201270325A1 (en)
IL (1) IL218306B (en)
IN (1) IN2012DN01911A (en)
MX (1) MX2012002208A (en)
SG (2) SG178547A1 (en)
WO (1) WO2011031503A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034552B1 (en) 2009-05-11 2020-02-19 БЕРГ ЭлЭлСи Method for treatment or prevention of progression of oncological disorders
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
CN104703585A (en) 2012-10-09 2015-06-10 宝洁公司 Method of identifying synergistic cosmetic combinations
CN104704362B (en) 2012-10-09 2018-08-28 宝洁公司 The method of benefit active and the composition comprising it are assessed in identification
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
JP6731336B2 (en) * 2013-04-08 2020-07-29 バーグ エルエルシー Method of treating cancer using coenzyme Q10 combination therapy
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
CA2952615A1 (en) 2014-06-17 2015-12-23 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
EP3166971B1 (en) * 2014-07-07 2019-09-11 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
CN105044360A (en) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Application of RBP4 as colorectal cancer blood serum marker and diagnostic kit
CN106053813A (en) * 2016-06-25 2016-10-26 林森 Immunohistochemical kit for detecting PDK1 expression quantity of nasopharyngeal carcinoma, and application of immunohistochemical kit
CN106947010B (en) * 2017-04-06 2018-12-11 哈尔滨工业大学 A method of polymerizeing induction self assembly in situ using light-initiated RAFT and prepares protein base nanoparticle
EP3634391A4 (en) * 2017-05-17 2021-02-24 Berg LLC Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CN107226862A (en) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 The preparation method of specific human EWS FLI1 fusion protein antibody and preparing Ewing sarcoma diagnose antibody reagent application
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. Data compression and communication using machine learning
WO2020206449A1 (en) * 2019-04-05 2020-10-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating tumors using transcription inhibition and dna damage
IL305697A (en) * 2021-03-05 2023-11-01 Univ Central Florida Res Found Inc Chaperonin-containing tcp-1 inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1853600A (en) * 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
US20050164196A1 (en) * 2002-04-17 2005-07-28 Dressman Marlene M. Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2006345701A (en) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd Method for judging responsiveness to taxans
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
ME01881B (en) * 2004-01-22 2014-12-20 Univ Miami Topical co-enzyme q10 formulations and methods of use
MXPA06013079A (en) * 2004-05-14 2007-10-08 Ludwig Inst Cancer Res Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib.
US8337851B2 (en) * 2005-05-18 2012-12-25 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1930445B1 (en) * 2005-09-02 2010-03-31 Toray Industries, Inc. Kit and method for detection of urothelial cancer
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8030013B2 (en) 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
WO2009051277A1 (en) * 2007-10-18 2009-04-23 Medical Proteoscope Co., Ltd. Method for prediction of postoperative prognosis, and diagnosis kit

Also Published As

Publication number Publication date
IL218306A0 (en) 2012-04-30
KR20120050495A (en) 2012-05-18
EP2470169A2 (en) 2012-07-04
IL218306B (en) 2018-05-31
MX2012002208A (en) 2012-06-12
US20130266557A1 (en) 2013-10-10
IN2012DN01911A (en) 2015-07-24
AU2016277749A1 (en) 2017-02-02
CN108245497A (en) 2018-07-06
SG178547A1 (en) 2012-03-29
CA2772068A1 (en) 2011-03-17
EA201270325A1 (en) 2012-11-30
CN102548549A (en) 2012-07-04
BR112012004237A2 (en) 2016-04-05
KR101572463B1 (en) 2015-11-27
JP2016136938A (en) 2016-08-04
EP2470169A4 (en) 2013-03-13
BR112012004237A8 (en) 2016-10-04
WO2011031503A3 (en) 2011-07-21
US20110064747A1 (en) 2011-03-17
CR20120120A (en) 2012-07-04
AU2010292532A1 (en) 2012-04-05
CA2772068C (en) 2017-03-21
JP2013503175A (en) 2013-01-31
WO2011031503A2 (en) 2011-03-17
JP6159085B2 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
IL218306A0 (en) Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
IL216295A0 (en) Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
GB0902784D0 (en) Plasma reactor
EP2386179A4 (en) Method for generating reference signals
PT3130396T (en) Spray-drying process
IL215169A0 (en) Isoxazole -pyridine derivatives as gaba modulators
ZA201106124B (en) Mechatronic locking apparatus
EP2561837A4 (en) Stent for bifurcated vessel
HK1165975A1 (en) Eyeglasses for treatment of a defined condition
EP2479781A4 (en) Plasma etching apparatus
PL2336289T3 (en) A spray-drying process
PT2542400E (en) Holding unit for a rotatable middelmould of an injectoin unit
EP2529395A4 (en) Method for improving plating on non-concuctive substrates
PL2406363T3 (en) A spray-drying process
EP2412004A4 (en) Methods of forming patterns on substrates
PL2569165T4 (en) A method of printing
EP2592911A4 (en) Plasma-generating apparatus
HK1163663A1 (en) Rifamycin derivatives
ZA201008192B (en) A phytosystem for treatment of sewage
EP2416351A4 (en) Plasma etching apparatus
PL2359367T3 (en) Process control of tolerance rings
GB0906836D0 (en) Consumable component kit
EP2615192A4 (en) Process for producing carburized part
HK1171226A1 (en) Azaindole glucokinase activators
ZA201202290B (en) A process for treating an effluent